A new paradigm in ulcerative colitis: Regulatory T cells are key factor which induces/exacerbates UC through an immune imbalance

Molecular Immunology

Volumn 54, Issue 2, 2013, Pages 173-180

  Hanai, Hiroyuki ^a   Iida, Takayuki ^a   Ikeya, Kentaro ^a   Abe, Jinrou ^a   Maruyama, Yasuhiko ^b   Shimura, Teruyuki ^b   Sugimoto, Ken ^c   Watanabe, Fumitoshi ^a  

^a Hamamatsu South Hospital   (Japan)

^b FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Activated Treg cell; Effector memory T cell; Leukocytapheresis; Regulatory T cell; Resting Treg cell; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DIZZINESS; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN CELL; LEUKAPHERESIS; LEUKOCYTAPHERESIS; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; COLITIS, ULCERATIVE; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84871837257     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.11.015     Document Type: Article

References (54)

1. Andoh A., Ogawa A., Kitamura K., et al. Suppression of interleukin-1beta-and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. Journal of Gastroenterology 2004, 39:1150-1157.
2. Andoh A., Tsujikawa T., lnatomi O., et al. Leukocytapheresis therapy modulates circulating T cell subsets in patients with ulcerative colitis. Therapeutic Apheresis and Dialysis 2005, 9:270-276.
3. Bamias G., Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Current Opinion in Gastroenterology 2007, 23:365-369.
4. Bettelli E., Oukka M., Kuchroo V.K. TH-17 cells in the circle of immunity and autoimmunity. Nature Immunology 2008, 8:345-350.
5. Blumberg R.S., Strober W. Prospects for research in inflammatory bowel disease. JAMA 2001, 285:643-647.
6. Boschetti G., Nancey S., Sardi F., et al. Therapy with anti-TNFα antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases. Inflammatory Bowel Diseases 2011, 17:160-170.
7. Crome S.Q., Clive B., Wang A.Y., et al. Inflammatory effects of ex vivo human Th17 cells are suppressed by regulatory T cells. Journal of Immunology 2010, 185:3199-3208.
8. D'Odorico A., D'Inca R., Mestriner C., et al. Influence of disease site and activity on peripheral neutrophil function in inflammatory bowel disease. Digestive Diseases and Sciences 2000, 45:1594-1600.
9. Eastaff-Leung N., Mabarrack N., Barbour A., et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. Journal of Clinical Immunology 2010, 30:80-89.
10. Evans H.G., Suddason T., Jackson I., et al. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:17034-17039.
11. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
12. Fukunaga K., Fukuda Y., Yokoyama Y., et al. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. Journal of Gastroenterology 2006, 41:524-532.
13. Hanai H., Watanabe F., Takeuchi K., et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clinical Gastroenterology and Hepatology 2003, 1:28-35.
14. Hanai H., Watanabe F., Yamada M., et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004, 70:36-44.
15. Hanai H., Iida T., Takeuchi K., et al. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World Journal of Gastroenterology 2005, 11:3085-3090.
16. Hanai H., Iida T., Takeuchi K., et al. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. American Journal of Gastroenterology 2008, 103:1210-1216.
17. Hanai H., Takeda Y., Eberhardson M., et al. The mode of actions of the Adacolumn therapeutic leukocytapheresis in patients with inflammatory bowel disease: a concise review. Clinical and Experimental Immunology 2010, 163:50-58.
18. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases 2006, 12(Suppl. 1):S3-S9.
19. Hart A.L., Kamm M.A., Knight S.C., et al. Prospective evaluation of intestinal homing memory T cells in ulcerative colitis. Inflammatory Bowel Diseases 2004, 10:496-503.
20. Hermanowicz A., Sliwinski Z., Nawarska Z. Humoral immune system and ulcerative colitis activity. I. Serum immunoglobulins and C-reactive protein levels. Archivum Immunologiae et Therapiae Experimentalis 1984, 32:501-508.
21. Kamikozuru K., Fukunaga K., Hirota S., et al. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clinical and Experimental Immunology 2009, 156:320-327.
22. Kanai T., Makita S., Kawamura T., et al. Extracorporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis therapy for ulcerative colitis. Inflammatory Bowel Diseases 2007, 13:284-290.
23. Kashiwagi N., Saniabadi A., Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Digestive Diseases and Sciences 2002, 47:1334-1341.
24. Koch S., Kucharzik T., Heidemann J., et al. Investigating the role of proinflammatory CD16+ monocytes in the pathogenesis of inflammatory bowel disease. Clinical and Experimental Immunology 2010, 161:332-341.
25. Lampinen M., Carlson M., Sangfelt P. IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Digestive Diseases and Sciences 2001, 46:2004-2009.
26. Linterman M.A., Pierson W., Lee S.K., et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nature Medicine 2011, 17:975-982.
27. Lohr J., Knoechel B., Wang J.J., et al. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. Journal of Experimental Medicine 2006, 203:2785-2791.
28. Mackay I.R., Wall A.J., Goldstein G. Response to azathioprine in ulcerative colitis. Report of 7 cases. American Journal of Digestive Diseases 1966, 11:536-545.
29. Mayer L. Evolving paradigms in the pathogenesis of IBD. Journal of Gastroenterology 2010, 45:9-16.
30. McGovern D., Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut 2007, 56:1333-1336.
31. Meyers S., Sachar D.B., Goldberg J.D., et al. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis: a prospective, randomized, double blind clinical trial. Gastroenterology 1983, 85:351-357.
32. Mitsuyama K., Suzuki A., Matsumoto S., et al. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clinical and Experimental Immunology 2005, 141:130-140.
33. Mitsuyama K., Andoh A., Matsuda J., et al. Mobilization of bone marrow cells by leukocytapheresis in patients with ulcerative colitis. Therapeutic Apheresis and Dialysis 2008, 12:271-277.
34. Miyara M., Yoshioka Y., Kitoh A., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
35. Moertel C.G., Bargen J.A. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Annals of Internal Medicine 1959, 51:879-889.
36. Nikolaus S., Bauditz J., Gionchetti P. Increased secretion of proinflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 1998, 42:470-476.
37. Oldenburg B., van Kats-Renaud H., Koningsberger J.C., et al. Chemiluminescence in inflammatory bowel disease patients: a parameter of inflammatory activity. Clinica Chimica Acta 2001, 20:151-156.
38. Ouyang W. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
39. Papadakis K.A., Targan S.R. Role of cytokines in pathogenesis of inflammatory bowel disease. Annual Review of Medicine 2000, 51:289-298.
40. Rachmilewitz D. (on behalf of an international study group). Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. British Medical Journal 1989, 298:82-86.
41. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005, 353:2462-2476.
42. Sallusto F. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
43. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annual Review of Immunology 2004, 22:745-763.
44. Sanchez-Munoz F., Dominguez-Lopez A., Yamamoto-Furusho J.K. Role of cytokines in inflammatory bowel disease. World Journal of Gastroenterology 2008, 14:4280-4288.
45. Sarra M., Pallone F., MacDonald T.T., et al. IL-23/IL-17 axis in IBD. Inflammatory Bowel Diseases 2010, 16:1808-1813.
46. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature Clinical Practice Gastroenterology & Hepatology 2006, 3:390-407.
47. Sawada K., Ohnishi K., Kosaka T., et al. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Therapeutic Apheresis 1997, 1:207-211.
48. Sawada K., Muto T., Shimoyama T., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Current Pharmaceutical Design 2003, 9:307-321.
49. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine 1987, 317:1625-1629.
50. Shimoyama T., Sawada K., Hiwatashi N., et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. Journal of Clinical Apheresis 2001, 16:1-9.
51. Sugimoto K., Ogawa A., Mizoguchi E., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. Journal of Clinical Investigation 2008, 118:534-544.
52. Truelove S.C., Witts L.J. Cortisone and corticotrophin in ulcerative colitis. British Medical Journal 1959, 34:387-394.
53. Yagi Y., Andoh A., Inatomi O., et al. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. Journal of Gastroenterology 2006, 41:540-546.
54. Yamaji K., Yang K., Tsuda H., et al. Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Therapeutic Apheresis 2002, 6:402-412.